Ret Proto-Oncogene antibody

Catalog No. ABIN498621

Product Details anti-Ret Proto-Oncogene Antibody

Target: Ret Proto-Oncogene (RET)

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Ret Proto-Oncogene antibody is un-conjugated

Application: Western Blotting (WB)

Specificity: This antibody detects endogenous levels of Ret protein. (region surrounding Trp1056)

Cross-Reactivity (Details): Species reactivity (expected):Mouse and Rat.
Species reactivity (tested):Human.

Purification: Affinity chromatography using epitope-specific immunogen

Purity: > 95 % (by SDS-PAGE)

Application Details

Application Notes: Western blot: 1: 500 - 1: 1000.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Concentration: 1.0 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.2, 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: Store at 2 - 8 °C for up to one month or (in aliquots) at -20 °C for longer.

Target Details for Ret Proto-Oncogene

Target: Ret Proto-Oncogene (RET)

Alternative Name: RET (RET Products)

Synonyms: c-ret antibody, cret antibody, etID315074.13 antibody, ret1 antibody, wu:fd13h01 antibody, X-ret antibody, ret-A antibody, xret antibody, RET antibody, MTC1 antibody, CDHF12 antibody, CDHR16 antibody, HSCR1 antibody, MEN2A antibody, MEN2B antibody, PTC antibody, RET-ELE1 antibody, RET51 antibody, RET9 antibody, c-Ret antibody, ret proto-oncogene receptor tyrosine kinase antibody, ret proto-oncogene S homeolog antibody, ret proto-oncogene antibody, ret antibody, ret.S antibody, RET antibody, Ret antibody

Background: The Ret proto-oncogene is structurally related to the growing family of tyrosine kinase transmembrane receptors and is involved in GDNF signaling. By alternative splicing, two isoforms of the Ret proto-oncogene product are generated. The isoforms differ from each other by having either 9 or 51 carboxy terminal amino acids. The Ret gene products include two glycosylated proteins in tunicamycin treated cells, a non-glycosylated protein consistent with the predicted Ret molecular weight based on sequence analysis. Tumorspecific rearrangements of the Ret proto-oncogene have been identified in papillary thyroid carcinomas leading to the formation of different transforming fusion proteins sharing the tyrosine kinase domain of Ret. In contrast to the Ret proto-oncogene, the rearranged forms are constitutively phosphorylated on tyrosine and are translocated from the membrane to the cytoplasm.Synonyms: C-ret, CDHF12, Cadherin family member 12, Proto-oncogene tyrosine-protein kinase receptor ret

Molecular Weight: approx. 175 kDa

Gene ID: 5979

NCBI Accession: NP_066124

UniProt: P07949

Pathways: RTK Signaling, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation